ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
ViiV Healthcare announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be “totally or very acceptable” vs 48% for lenacapavir (LEN) injections. Data presented at EACS 2025 also showed 90% of HIV-negative adults and 86% of healthcare providers preferred CAB LA injections over LEN injections after a single dose, and ISR events were more frequent and visible with LEN than with CAB LA.
Read the full company press release here.
Source : ViiV Healthcare
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.